Persistence of atovaquone in human sera following treatment: inhibition of Plasmodium falciparum development in vivo and in vitro.
Published pharmacokinetic data indicate that after treatment of patients with therapeutic doses of atovaquone/proguanil hydrochloride (Malarone, GlaxoSmithKline Research Triangle Park, NC), the plasma half-lives of these drugs are 70h and 15h, respectively. However, using two biologic assays (mosqui...
Main Authors: | Butcher, G, Sinden, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2003
|
Similar Items
-
Inhibition of the mosquito transmission of Plasmodium berghei by Malarone (atovaquone-proguanil).
by: Butcher, G, et al.
Published: (2000) -
Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria.
by: Chiodini, P, et al.
Published: (1995) -
The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum.
by: Chotivanich, K, et al.
Published: (2012) -
Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports.
by: Färnert, A, et al.
Published: (2003) -
Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.
by: McKeage, K, et al.
Published: (2003)